{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:52:02Z","timestamp":1782327122219,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"crossref","award":["\u201c13th Five-Year\u201d National Major New Drug Projects No.2017ZX09304031-001"],"award-info":[{"award-number":["\u201c13th Five-Year\u201d National Major New Drug Projects No.2017ZX09304031-001"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["\u201c13th Five-Year\u201d National Major New Drug Projects No.2017ZX09101001-002-001"],"award-info":[{"award-number":["\u201c13th Five-Year\u201d National Major New Drug Projects No.2017ZX09101001-002-001"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40261-019-00786-5","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T10:04:33Z","timestamp":1556013873000},"page":"643-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-2189","authenticated-orcid":false,"given":"Xueting","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"issue":"1","key":"786_CR1","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1186\/ar2368","volume":"10","author":"QY Zeng","year":"2008","unstructured":"Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10(1):R17.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"786_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00296-012-2605-z","volume":"33","author":"J Zhen","year":"2013","unstructured":"Zhen J, Ling-Yun S, Yao-Hong Z, Xiang-Dang W, Jie-Ping P, Miao-Jia Z, et al. Death-related factors of systemic lupus erythematosus patients associated with the course of disease in Chinese populations: multicenter and retrospective study of 1,958 inpatients. Rheumatol Int. 2013;33(6):1541\u20136.","journal-title":"Rheumatol Int"},{"issue":"9","key":"786_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"R Giacomelli","year":"2017","unstructured":"Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren\u2019s syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911\u201324.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"786_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","volume":"13","author":"LS Tam","year":"2004","unstructured":"Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004;13(8):601\u20134.","journal-title":"Lupus."},{"issue":"7","key":"786_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1191\/096120301678416033","volume":"10","author":"CF Remer","year":"2001","unstructured":"Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001;10(7):480\u20133.","journal-title":"Lupus."},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"832916","DOI":"10.1155\/2015\/832916","volume":"2015","author":"GF Dong","year":"2015","unstructured":"Dong GF, Zhang X, He DN, Li L, Zhang GF. Effect of leflunomide on the abnormal expression of lipid rafts and F-actin in B lymphocytes from patients with systemic lupus erythematosus. J Immunol Res. 2015;2015:832916.","journal-title":"J Immunol Res."},{"issue":"5","key":"786_CR7","doi-asserted-by":"publisher","first-page":"R232","DOI":"10.1186\/ar4075","volume":"14","author":"SW Lee","year":"2012","unstructured":"Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther. 2012;14(5):R232.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"786_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1586\/17474124.2016.1127756","volume":"10","author":"JG Stine","year":"2016","unstructured":"Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517\u201336.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"786_CR9","volume-title":"Teriflunomide sodium hepatocyte toxicity experimental report","author":"P Guoyu","year":"2013","unstructured":"Guoyu P. Teriflunomide sodium hepatocyte toxicity experimental report. Shanghai: Research Center for Drug Safety Evaluation, Shanghai Institute of Materia Medica; 2013."},{"issue":"24","key":"786_CR10","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.jchromb.2010.06.028","volume":"878","author":"JM Parekh","year":"2010","unstructured":"Parekh JM, Vaghela RN, Sutariya DK, Sanyal M, Yadav M, Shrivastav PS. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(24):2217\u201325.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"6","key":"786_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","volume":"41","author":"B Rozman","year":"2002","unstructured":"Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41(6):421\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"786_CR12","unstructured":"US Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review: Teriflunomide. 2011. pp. 1\u2013183.\u00a0\n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202992Orig1s000ClinpharmR.pdf\n                    \n                  .\u00a0Accessed 21 Apr 2019."},{"key":"786_CR13","unstructured":"Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators\u2019 Group. J Rheumatol Suppl. 1998;53:27\u201332."},{"key":"786_CR14","unstructured":"US Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review: Lelfunomide (Arava). 1998. pp. 1\u201355. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20905_ARAVA_BIOPHARMR.PDF\n                    \n                  .\u00a0Accessed 21 Apr 2019."},{"key":"786_CR15","unstructured":"US Food and Drug Administration. Guidance for Industry: Applications Covered by Section\u00a0505(b)(2) (draft guidance). 1999. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm079345.pdf\n                    \n                  . Accessed 21 Apr 2019."},{"key":"786_CR16","unstructured":"China National Medical Products Administration. Good Clinical Practice of Pharmaceutical Products. 2003.\u00a0\n                    http:\/\/samr.cfda.gov.cn\/WS01\/CL0053\/24473.html\n                    \n                  . Accessed 21 Apr 2019."},{"key":"786_CR17","unstructured":"International Conference on Harmonisation. ICH Topic E 6 (R1): Guideline for Good Clinical Practice. 1996.\u00a0\n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf\n                    \n                  . Accessed 21 Apr 2019."},{"issue":"20","key":"786_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.\u00a0","journal-title":"JAMA"},{"issue":"3","key":"786_CR19","doi-asserted-by":"publisher","first-page":"e4420","DOI":"10.1002\/bmc.4420","volume":"33","author":"X Yao","year":"2019","unstructured":"Yao X, Liu Y, Song L, Jiang J, Xiao F, Liu D, et al. Development of a simple HPLC-MS\/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. Biomed Chromatogr. 2019;33(3):e4420.","journal-title":"Biomed Chromatogr"},{"key":"786_CR20","unstructured":"US Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. Center for Drug Evaluation and Research (CDER). 2013. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf\n                    \n                  . Accessed 21 Apr 2019."},{"key":"786_CR21","unstructured":"China National Medical Product Administration. Guideline on bioanalytical method validation. China Pharmacopeia (version 2015). 2015. Part 2, pp. 363\u20138."},{"issue":"7","key":"786_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/ard.2007.086264","volume":"68","author":"E Kis","year":"2009","unstructured":"Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009;68(7):1201\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"786_CR23","first-page":"426","volume":"33","author":"T Soukup","year":"2015","unstructured":"Soukup T, Dosedel M, Nekvindova J, Toms J, Vlcek J, Pavek P. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(3):426\u201332.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"786_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00008571-200301000-00004","volume":"13","author":"CP Zamber","year":"2003","unstructured":"Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003;13(1):19\u201328.","journal-title":"Pharmacogenetics."},{"issue":"2","key":"786_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00228-010-0916-0","volume":"67","author":"KA Kim","year":"2011","unstructured":"Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol. 2011;67(2):129\u201334.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"786_CR26","first-page":"551","volume":"23","author":"J Li","year":"2002","unstructured":"Li J, Yao HW, Jin Y, Zhang YF, Li CY, Li YH, et al. Pharmacokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin. 2002;23(6):551\u20135.","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"786_CR27","doi-asserted-by":"publisher","first-page":"e0144548","DOI":"10.1371\/journal.pone.0144548","volume":"10","author":"H Cao","year":"2015","unstructured":"Cao H, Rao Y, Liu L, Lin J, Yang H, Zhang X, et al. The efficacy and safety of leflunomide for the treatment of lupus nephritis in chinese patients: systematic review and meta-analysis. PLoS One. 2015;10(12):e0144548.","journal-title":"PLoS One"},{"issue":"7","key":"786_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/0961203308089408","volume":"17","author":"HY Wang","year":"2008","unstructured":"Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008;17(7):638\u201344.","journal-title":"Lupus."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00786-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00786-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00786-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T23:19:14Z","timestamp":1587511154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00786-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00786-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"23 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the \u201813th Five-Year\u2019 National Major New Drug Projects (no. 2017ZX09304031-001 and no. 2017ZX09101001-002-001) [Ministry of Science and Technology of the People\u2019s Republic of China].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xueting Yao, Yiwen Wu, Ji Jiang, Pei Hu, Dongyang Liu and Xia Chen declare no financial relationships with any organizations that might have an interest in the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this clinical study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments. The study was approved by the Peking Union Medical College Hospital Ethics Committee (approval number: HS2015022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Prior to study entry, all subjects reviewed and signed an informed consent document explaining the study procedures and potential risks.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}